##################################################################################
# Document Properties Section

SET DOCUMENT Name = "Document name"
SET DOCUMENT Description = "Document description"
SET DOCUMENT Version = "1.0"
SET DOCUMENT Copyright = "Copyright (c) 2012, hanan1. All Rights Reserved."
SET DOCUMENT Authors = "hanan1"
SET DOCUMENT Licenses = "Document license"
SET DOCUMENT ContactInfo = "your@email.com"

##################################################################################
# Definitions Section

# NAMESPACE URLS

DEFINE NAMESPACE ADO AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/ADO.belns"
DEFINE NAMESPACE AFFX AS URL "http://resource.belframework.org/belframework/20150611/namespace/affy-probeset-ids.belns"
DEFINE NAMESPACE BRCO AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/BRCO.belns"
DEFINE NAMESPACE CHEBI AS URL "http://resource.belframework.org/belframework/20150611/namespace/chebi.belns"
DEFINE NAMESPACE CHEBIID AS URL "http://resource.belframework.org/belframework/20150611/namespace/chebi-ids.belns"
DEFINE NAMESPACE CHEMBL AS URL "http://belief-demo.scai.fraunhofer.de/openbel/repository/namespaces/chembl-names.belns"
DEFINE NAMESPACE CHEMBLID AS URL "http://belief-demo.scai.fraunhofer.de/openbel/repository/namespaces/chembl-ids.belns"
DEFINE NAMESPACE CTO AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/CTO.belns"
DEFINE NAMESPACE DO AS URL "http://resource.belframework.org/belframework/20150611/namespace/disease-ontology.belns"
DEFINE NAMESPACE DOID AS URL "http://resource.belframework.org/belframework/20150611/namespace/disease-ontology-ids.belns"
DEFINE NAMESPACE EGID AS URL "http://resource.belframework.org/belframework/20150611/namespace/entrez-gene-ids.belns"
DEFINE NAMESPACE FlyBase AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/Dmel.belns"
DEFINE NAMESPACE GOBP AS URL "http://resource.belframework.org/belframework/20150611/namespace/go-biological-process.belns"
DEFINE NAMESPACE GOBPID AS URL "http://resource.belframework.org/belframework/20150611/namespace/go-biological-process-ids.belns"
DEFINE NAMESPACE GOCC AS URL "http://resource.belframework.org/belframework/20150611/namespace/go-cellular-component.belns"
DEFINE NAMESPACE GOCCID AS URL "http://resource.belframework.org/belframework/20150611/namespace/go-cellular-component-ids.belns"
DEFINE NAMESPACE HGNC AS URL "http://resource.belframework.org/belframework/20150611/namespace/hgnc-human-genes.belns"
DEFINE NAMESPACE LMSD AS URL "http://belief-demo.scai.fraunhofer.de/openbel/repository/namespaces/LMSD.belns"
DEFINE NAMESPACE MESHC AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-chemicals.belns"
DEFINE NAMESPACE MESHCID AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-chemicals-ids.belns"
DEFINE NAMESPACE MESHCS AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-cellular-structures.belns"
DEFINE NAMESPACE MESHCSID AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-cellular-structures-ids.belns"
DEFINE NAMESPACE MESHD AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-diseases.belns"
DEFINE NAMESPACE MESHDID AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-diseases-ids.belns"
DEFINE NAMESPACE MESHPP AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-processes.belns"
DEFINE NAMESPACE MESHPPID AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-processes-ids.belns"
DEFINE NAMESPACE MGI AS URL "http://resource.belframework.org/belframework/20150611/namespace/mgi-mouse-genes.belns"
DEFINE NAMESPACE NIFT AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/NIFT.belns"
DEFINE NAMESPACE NTN AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/Nutrition.belns"
DEFINE NAMESPACE PDO AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/PDO.belns"
DEFINE NAMESPACE PH AS URL "http://belief-demo.scai.fraunhofer.de/openbel/repository/namespaces/Placeholder.belns"
DEFINE NAMESPACE PMIBP AS URL "http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmibp.belns"
DEFINE NAMESPACE PMICHEM AS URL "http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmichem.belns"
DEFINE NAMESPACE PMICOMP AS URL "http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmicomp.belns"
DEFINE NAMESPACE PMIDIS AS URL "http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmidis.belns"
DEFINE NAMESPACE PMIPFAM AS URL "http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmipfam.belns"
DEFINE NAMESPACE PTS AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/PTS.belns"
DEFINE NAMESPACE RGD AS URL "http://resource.belframework.org/belframework/20150611/namespace/rgd-rat-genes.belns"
DEFINE NAMESPACE SCHEM AS URL "http://resource.belframework.org/belframework/20150611/namespace/selventa-legacy-chemicals.belns"
DEFINE NAMESPACE SCOMP AS URL "http://resource.belframework.org/belframework/20150611/namespace/selventa-named-complexes.belns"
DEFINE NAMESPACE SDIS AS URL "http://resource.belframework.org/belframework/20150611/namespace/selventa-legacy-diseases.belns"
DEFINE NAMESPACE SFAM AS URL "http://resource.belframework.org/belframework/20150611/namespace/selventa-protein-families.belns"
DEFINE NAMESPACE SP AS URL "http://resource.belframework.org/belframework/20150611/namespace/swissprot.belns"
DEFINE NAMESPACE SPID AS URL "http://resource.belframework.org/belframework/20150611/namespace/swissprot-ids.belns"
DEFINE NAMESPACE dbSNP AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/SNP.belns"


# ANNOTATION URLS

DEFINE ANNOTATION Anatomy AS URL "http://resource.belframework.org/belframework/20131211/annotation/anatomy.belanno"
DEFINE ANNOTATION BodyRegion AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-body-region.belanno"
DEFINE ANNOTATION CardiovascularSystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-cardiovascular-system.belanno"
DEFINE ANNOTATION Cell AS URL "http://resource.belframework.org/belframework/20131211/annotation/cell.belanno"
DEFINE ANNOTATION CellLine AS URL "http://resource.belframework.org/belframework/20131211/annotation/cell-line.belanno"
DEFINE ANNOTATION CellStructure AS URL "http://resource.belframework.org/belframework/20131211/annotation/cell-structure.belanno"
DEFINE ANNOTATION DigestiveSystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-digestive-system.belanno"
DEFINE ANNOTATION Disease AS URL "http://resource.belframework.org/belframework/20131211/annotation/disease.belanno"
DEFINE ANNOTATION FluidAndSecretion AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-fluid-and-secretion.belanno"
DEFINE ANNOTATION HemicAndImmuneSystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-hemic-and-immune-system.belanno"
DEFINE ANNOTATION IntegumentarySystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-integumentary-system.belanno"
DEFINE ANNOTATION MeSHAnatomy AS URL "http://resource.belframework.org/belframework/20131211/annotation/mesh-anatomy.belanno"
DEFINE ANNOTATION MeSHDisease AS URL "http://resource.belframework.org/belframework/20131211/annotation/mesh-diseases.belanno"
DEFINE ANNOTATION NervousSystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-nervous-system.belanno"
DEFINE ANNOTATION RespiratorySystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-respiratory-system.belanno"
DEFINE ANNOTATION Species AS URL "http://resource.belframework.org/belframework/20131211/annotation/species-taxonomy-id.belanno"
DEFINE ANNOTATION Tissue AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-tissue.belanno"
DEFINE ANNOTATION UrogenitalSystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-urogenital-system.belanno"

##################################################################################
# Statements Section

SET STATEMENT_GROUP = "Group 1"

# Add statements below this comment

SET Citation={"PubMed","Neuropharmacology. 2008 Jan;54(1):16-22. Epub 2007 Jun 2.","17631917"}
SET Evidence="Microglial cell activation and migration play an important role in neuroinflammation propagation. 
While it is known that the lipid transmitter palmitoylethanolamide (PEA) regulates microglial migration by interacting with a cannabinoid-like receptor,
the production and inactivation of this lipid by microglia has never been addressed directly. Here we show that the mouse microglial cell line BV-2 produces and hydrolyzes PEA."
SET Species="10090"
bp(GOBP:"microglial cell activation") -- path(ADO:neuroinflammation)
bp(GOBP:"microglial cell migration") -- path(ADO:neuroinflammation)
complex(a(CHEBI:"palmitoyl ethanolamide"),p(HGNC:CNR1)) -> bp(GOBP:"microglial cell activation")
SET Cell="microglial cell"
SET CellLine="MEF (C57BL/6) cell"
a(BRCO:microglia) negativeCorrelation a(CHEBI:"palmitoyl ethanolamide") 
UNSET Cell
UNSET CellLine


SET Evidence="The carbamate compound URB602 inhibits PEA hydrolysis in BV-2 cell homogenates and increases PEA levels in intact cells, whereas the FAAH inhibitor URB597 and serine-hydrolase inhibitor MAFP do not affect PEA levels in intact cells. 
This unique pharmacological profile of inhibitors on PEA hydrolysis suggests the involvement of a previously undescribed enzyme that degrades PEA.
This enzyme expressed by microglia constitutes a promising target for controlling the propagation of neuroinflammation."
SET CellLine="MEF (C57BL/6) cell"
a("carbamate compound URB602")  negativeCorrelation a(CHEBI:"palmitoyl ethanolamide")
a("FAAH inhibitor URB597") causesNoChange a(CHEBI:"palmitoyl ethanolamide")
a("serine-hydrolase inhibitor MAFP")causesNoChange a(CHEBI:"palmitoyl ethanolamide")
UNSET CellLine
SET Cell="microglial cell"
a("carbamate compound URB602") -| path(ADO:neuroinflammation)
UNSET Cell

UNSET Species 
############################################################################
SET Citation={"PubMed","Nat Clin Pract Neurol. 2007 Sep;3(9):496-504.","17805244"}
SET Evidence="The finding that activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) suppresses inflammation in peripheral macrophages and in models of human autoimmune disease instigated the evaluation of this salutary action for the treatment of CNS disorders with an inflammatory component. "
SET Cell="macrophage"
p(HGNC:PPARG) -| bp(GOBP:"inflammatory response")
UNSET Cell
SET MeSHDisease ="Autoimmune Diseases"
p(HGNC:PPARG) -| bp(GOBP:"inflammatory response")
p(HGNC:PPARG) -| path(MESHD:"Demyelinating Autoimmune Diseases, CNS")
UNSET MeSHDisease


SET Evidence="The fact that NSAIDs delay the onset of and reduce the risk of 
developing Alzheimer's disease (AD), while also binding to and activating PPARgamma, 
led to the hypothesis that one dimension of NSAID protection in AD is mediated by 
PPARgamma. Several lines of evidence from experiments using AD-related transgenic 
cellular and animal models have supported this hypothesis. "
SET Species="10090"
a(CHEBI:"non-steroidal anti-inflammatory drug") -| path(MESHD:"Alzheimer Disease")
complex(a(CHEBI:"non-steroidal anti-inflammatory drug"),p(HGNC:PPARG)) -| path(MESHD:"Alzheimer Disease")


  
SET Evidence="The capacity of PPARgamma agonists to elicit anti-inflammatory, 
anti-amyloidogenic and insulin-sensitizing effects might account for their 
observed protective effects. Several clinical trials employing PPARgamma 
agonists have yielded promising results, and further trials are in preparation. 
Positive outcomes following PPARgamma administration have been obtained in animal models of other neurodegenerative diseases, including Parkinson's disease and amyotrophic lateral sclerosis, both of which are associated with a considerable degree of neuroinflammation "

p(HGNC:PPARG) -- path(ADO:"neurodegenerative_disease")
p(HGNC:PPARG) -| path(MESHD:"Parkinson Disease")
p(HGNC:PPARG) -| path(DO:"amyotrophic lateral sclerosis")
path(MESHD:"Parkinson Disease") -- path(ADO:neuroinflammation)
path(DO:"amyotrophic lateral sclerosis") -- path(ADO:neuroinflammation)
UNSET Species


SET Evidence="Finally, activation of PPARgamma has been found to be protective in several models of multiple sclerosis. The verification of these findings in human cells prompted the initiation of clinical studies evaluating PPARgamma activation in patients with multiple sclerosis. "
SET Species="9606"
SET MeSHDisease="Multiple Sclerosis"
p(HGNC:PPARG) -- path(MESHD:"Multiple Sclerosis")
UNSET Species
UNSET MeSHDisease
#########################################################################
SET Citation={"PubMed","Glia. 2008 Jan 1;56(1):78-88.","17943953"}
SET Evidence="Blood-brain barrier (BBB) formed by brain microvascular endothelial cells (BMVEC) regulates the passage of molecules and leukocytes in and out of the brain. Activation of matrix metalloproteinases (MMPs) and alteration of basement membrane (BM) associated with BBB injury was documented in stroke patients. While chronic alcoholism is a risk factor for developing stroke, underlying mechanisms are not well understood."

SET MeSHAnatomy ="Brain"
SET Cell= {"endothelial cell","leukocyte"}
SET MeSHAnatomy="Blood-Brain Barrier"
a(GOCC:"basement membrane") -- path(MESHD:Stroke)
p(HGNC:MMP1)-- path(MESHD:Stroke)
bp(GOBP:"establishment of blood-brain barrier") --  bp(GOBP:"leukocyte migration")
UNSET MeSHAnatomy
UNSET Cell
UNSET MeSHAnatomy


SET Evidence="We hypothesized that ethanol (EtOH)-induced protein tyrosine kinase (PTK) signaling resulted a loss of BBB integrity via MMPs activation
and degradation of BM component, collagen IV. Treatment of BMVEC with EtOH or acetaldehyde (AA) for 2-48 h increased MMP-1, -2 and -9 activities
or decreased the levels of tissue inhibitors of MMPs (TIMP-1, -2) in a PTK-dependent manner without affecting protein tyrosine phosphatase activity.
 Using human BMVEC assembled into BBB models, we found that EtOH/AA diminished barrier tightness, augmented permeability, and monocyte migration across the BBB via activation of PTKs and MMPs."
SET Species="9606"
a(CHEBI:ethanol) -> p(HGNC:PTK2B) 
a("MMPs") -| a("Blood-Brain Barrier")
deg(a(GOCC:"basement membrane")) -| bp(GOBP:"establishment of blood-brain barrier")
deg(a(CHEBI:Collagen)) -| bp(GOBP:"establishment of blood-brain barrier")
a(CHEBI:ethanol) -| path(ADO:"Microvascular_Markers")
a(CHEBI:acetaldehyde) -| path(ADO:"Microvascular_Markers")
path(ADO:"Microvascular_Markers") negativeCorrelation p(HGNC:MMP1)
path(ADO:"Microvascular_Markers") negativeCorrelation p(HGNC:MMP2)
path(ADO:"Microvascular_Markers") negativeCorrelation p(HGNC:MMP9)
path(ADO:"Microvascular_Markers") -| p(HGNC:TIMP1)
path(ADO:"Microvascular_Markers") -| p(HGNC:TIMP21)

SET MeSHAnatomy="Blood-Brain Barrier"
a(CHEBI:ethanol) -| a("barrier tightness")
a(CHEBI:acetaldehyde) -| bp(GOBP:"regulation of vascular permeability")
a(CHEBI:acetaldehyde) -| bp(GOBP:"monocyte migration into blood stream")

UNSET MeSHAnatomy


SET Evidence="Enhanced PTK activity after EtOH exposure correlated with increased phosphorylated proteins of selective receptor and nonreceptor PTKs.
Up-regulation of MMPs activities and protein contents paralleled a decrease in collagen IV content, and inhibitors of EtOH metabolism, MMP-2 and -9, or PTK reversed all these effects."
a(CHEBI:ethanol) -> p(HGNC:PTK2B) 
p(HGNC:PTK2B,pmod(P)) positiveCorrelation p(HGNC:MMP1)
p(HGNC:PTK2B,pmod(P)) positiveCorrelation p(HGNC:MMP2)
p(HGNC:PTK2B,pmod(P)) positiveCorrelation p(HGNC:MMP9)
p(HGNC:PTK2B,pmod(P)) -| a(CHEBI:Collagen)
a(CHEBI:ethanol) positiveCorrelation p(HGNC:PTK2B)
a(CHEBI:ethanol) positiveCorrelation p(HGNC:MMP2)
a(CHEBI:ethanol) positiveCorrelation p(HGNC:MMP9)



SET Evidence="These findings suggest that alcohol associated BBB injury could be mediated by MMPs via BM protein degradation and could serve as a comorbidity factor for neurological disorders like stroke or neuroinflammation.
Furthermore, our preliminary experiments indicated that human astrocytes secreted high levels of MMP-1 and -9 following exposure to EtOH,
suggesting the role of BM protein degradation and BBB compromise as a result of glial activation by ethanol.
These results provide better understanding of multifaceted effects of alcohol on the brain and could help develop new therapeutic interventions."

a(CHEBI:alcohol) -- bp(GOBP:"negative regulation of establishment of blood-brain barrier")
p(HGNC:MMP1) -> bp(GOBP:"negative regulation of establishment of blood-brain barrier")
p(HGNC:MMP2) -> bp(GOBP:"negative regulation of establishment of blood-brain barrier")
p(HGNC:MMP9) -> bp(GOBP:"negative regulation of establishment of blood-brain barrier")
deg(a(GOCC:"basement membrane"))  -> bp(GOBP:"negative regulation of establishment of blood-brain barrier")                  
bp(GOBP:"negative regulation of establishment of blood-brain barrier") -> path(MESHD:Stroke)
bp(GOBP:"negative regulation of establishment of blood-brain barrier") -> path(ADO:neuroinflammation)

SET Cell="astrocyte"
a(BRCO:Astrocyte) -> p(HGNC:MMP1)
a(BRCO:Astrocyte) -> p(HGNC:MMP9)
p(HGNC:MMP1) -> a(CHEBI:ethanol)
p(HGNC:MMP1) -> a(CHEBI:ethanol)
a(CHEBI:ethanol) ->  bp(GOBP:"positive regulation of glial cell differentiation")
bp(GOBP:"positive regulation of glial cell differentiation") -> deg(a(GOCC:"basement membrane"))
bp(GOBP:"positive regulation of glial cell differentiation") -> bp(GOBP:"regulation of establishment of blood-brain barrier")
UNSET Species
UNSET Cell
######################################################
SET Citation={"PubMed","Anal Biochem. 2008 Feb 15;373(2):220-8. Epub 2007 Sep 29.","17981259"}
SET Evidence="The endocannabinoids anandamide and 2-arachidonoylglycerol, as well as several anandamide-related N-acylethanolamines,
belong to a family of lipid transmitter that regulate fundamental physiological processes, including neurotransmission and neuroinflammation.
Their precise quantification in biological matrices can be achieved by gas chromatography-mass spectrometry (GC-MS),
but this method typically requires multiple time-consuming purification steps such as solid-phase extraction followed by HPLC."
a(CHEBI:anandamide) -> path(ADO:neuroinflammation)
a(CHEBI:"2-arachidonoylglycerol") -> path(ADO:neuroinflammation)
complex(a(CHEBI:anandamide),a(CHEBI:" N-acylethanolamine")) -> path(ADO:neuroinflammation)  
a(CHEBI:anandamide) -> bp(GOBP:"modulation of synaptic transmission" )
a(CHEBI:"2-arachidonoylglycerol") -> bp(GOBP:"modulation of synaptic transmission" )
complex(a(CHEBI:anandamide),a(CHEBI:" N-acylethanolamine")) -> bp(GOBP:"modulation of synaptic transmission" ) 
        
 
########################################

SET Citation={"PubMed","J Neuroimmunol. 2008 Jan;193(1-2):38-51. Epub 2007 Nov 19.","18006081"}
SET Evidence="Collapsin Response Mediator Protein (CRMP)-2 is involved in T-cell polarization and migration. 
To address the role of CRMP2 in neuroinflammation, we analyzed its involvement in lymphocyte recruitment to the central nervous system in mouse infected with neurotropic and non-neurotropic virus strains (RABV, CDV)."
SET Species="10090"
p(DPYSL2 ) -- bp(GOBP:"T cell migration")
p(CRMP2) -- bp(GOBP:"regulation of establishment of T cell polarity ")
SET MeSHDisease ="Central Nervous System Diseases"
SET Cell="lymphocyte"
p(CRMP2) -- path(ADO:neuroinflammation)
path(ADO:neuroinflammation) -- path(MESHD:"Central Nervous System Viral Diseases")
UNSET MeSHDisease
UNSET Cell

SET Evidence="A sub-population of early-activated CD69+CD3+ T lymphocytes highly expressing CRMP2 (CRMP2hi) peaked in the blood, 
lymph nodes and brain of mice infected with neurotropic viruses, and correlated with severity of disease. "
SET Cell="lymphocyte"
#(T lymphocytes)
complex(p(HGNC:CD69),p(HGNC:CD3D)) -> p(HGNC:DPYSL2) 
UNSET Cell
SET Tissue="Lymph Nodes"
SET MeSHAnatomy ="Brain"
path(MESHD:"Central Nervous System Viral Diseases")-- path(MESHD:"Acute Disease")
UNSET Species
UNSET Tissue
UNSET MeSHAnatomy

SET Evidence="They displayed high migratory properties reduced by CRMP2 blocking antibody. These data point out the potential use of CRMP2 as a peripheral indicator of neuroinflammation."
p(HGNC:DPYSL2) biomarkerFor path(ADO:neuroinflammation)

#########################################################
SET Citation={"PubMed","J Neuroimmune Pharmacol. 2007 Mar;2(1):87-92. Epub 2007 Jan 9.","18040830"}
SET Evidence="Intranasal (IN) delivery of HIV-1 Tat in aging mice was investigated as a possible model for HIV-1 infection in the brain. After IN administration, the distribution of [(125)I]-labeled Tat in the brains of Swiss Webster mice was evaluated by autoradiography
and gamma counting. [(125)I]-labeled Tat was detected at the highest concentrations in the olfactory bulb, cervical nodes, and trigeminal nerve tract. In another experiment, APPSw transgenic mice were used to model chronic Tat exposure."
SET Species="10090"
path(MESHD:"Central Nervous System Viral Diseases") -> a("olfactory bulb")
path(MESHD:"Central Nervous System Viral Diseases") -> a("trigeminal nerve tract")
path(MESHD:"Central Nervous System Viral Diseases") -> a("cervical nodes")

SET Evidence=" The mice were treated intranasally with 6 mug Tat (n = 4) or vehicle (n = 4) three times per week for 4 weeks.
Total RNA was isolated from the frontal cortex, and differential gene expression analysis was performed using gene microarrays.
Gene ontology profiles indicated innate immunity, inflammatory and apoptotic responses."
a(GOCC:"cell cortex") -- bp(GOBP:"immune system process")
a(GOCC:"cell cortex") -- bp(GOBP:"inflammatory response")
a(GOCC:"cell cortex") -- bp(GOBP:"apoptotic process")

SET Evidence=" Five genes of interest in the Tat-treated mice that were significantly elevated in the microarrays were validated by RT-PCR. One gene,
the Toll-like receptor 9 (Tlr9), has previously been shown to activate signaling cascades leading to innate immunity and enhanced HIV-1 gene expression.
 A second gene, Fas, plays a key role in neuroinflammation. "
p(HGNC:TLR9) -> bp(GOBP:"innate immune response activating cell surface receptor signaling pathway")
g(HGNC:FAS) -> bp(GOBP:"Fas signaling pathway")
bp(GOBP:"Fas signaling pathway") -> path(ADO:neuroinflammation)

SET Evidence="Two cysteine-rich cytokines associated with chemotaxis were elevated: MCP-1 (Ccl2), which is chemotactic for monocytes, 
and Ccl17 (TARC), which is chemotactic for lymphocytes. Finally, the gene sestrin was significantly elevated and has been associated with 
oxidative stress, in particular amyloid beta-induced oxidative stress. This IN Tat model of neuroinflammation may be useful to study HIV-1-induced "
SET Cell="monocyte"
p(HGNC:CCL2 ) -- bp(GOBP:"lymphocyte chemotaxis")
UNSET Cell
SET Cell="lymphocyte"
p(HGNC:CCL17 ) --  bp(GOBP:"lymphocyte chemotaxis")
g(HGNC:SESN2) --  bp(GOBP:"response to oxidative stress")
UNSET Cell
#############################################3
SET Citation={"PubMed","Mol Immunol. 2008 Apr;45(7):2007-16. Epub 2007 Dec 3.","18061674"}
SET Evidence="Toll-like receptors (TLRs) response is critical in innate resistance to infection.
Alcohol consumption has been shown to suppress the inflammatory response mediated through TLR4, 
down regulating the production of inflammatory cytokines.
We recently reported that low concentrations of ethanol activate TLR4 signaling in astrocytes and triggers neuroinflammation."

complex(a(CHEBI:alcohol),p(HGNC:TLR4)) -> bp(GOBP:"inflammatory response")
SET Cell="astrocyte"
a(CHEBI:ethanol) negativeCorrelation p(HGNC:TLR4)
a(CHEBI:ethanol) negativeCorrelation path(ADO:neuroinflammation)
UNSET Cell

SET Evidence="Because macrophages are important cells in innate immunity, we investigate whether low concentrations of
ethanol could stimulate the TLR4 signaling response in murine RAW 264.7 macrophages,
and the mechanism involved in the ethanol-induced TLR4 activation.
Our results show that while ethanol, at high concentrations (100mM) or in the presence of the LPS,suppresses the TLR4 response, 
low to moderate levels (10-50mM) activate the TLR4 response and triggers the stimulation of the mitogen-activated protein kinases (MAPKs)
and the transcription factor NF-kappaB pathways, leading to the production of nitric oxide (NO) and inflammatory cytokines."

SET Cell="macrophage"
bp(GOBP:"macrophage activation") -- bp(GOBP:"immune system process")
UNSET Cell
SET CellLine="murine RAW 264.7 macrophages"
a(CHEBI:ethanol) positiveCorrelation p(HGNC:TLR4)
complex(a(CHEBI:ethanol),a(CHEBI:lipopolysaccharide)) -| p(HGNC:TLR4)
a(CHEBI:ethanol) positiveCorrelation p(HGNC:TLR4)
a(CHEBI:ethanol) positiveCorrelation bp(GOBP:"activation of MAPK activity")
a(CHEBI:ethanol) positiveCorrelation  bp(GOBP:"positive regulation of NF-kappaB transcription factor activity ") 
a(CHEBI:ethanol) -> a(CHEBI:"nitric oxide")
a(CHEBI:ethanol) -> bp(GOBP:"cytokine production involved in inflammatory response")
UNSET CellLine

SET Evidence="Pre-treatment with anti-TLR4 Abs abolishes the effects of ethanol on the production of cytokines. 
We also present evidence that stimulation with either ethanol or LPS induces translocation and clustering of TLR4 and signaling molecules (IRAK and MAPKs)
into lipid rafts. Treatment with either streptolysin-O or saponin, lipid rafts disrupting agents, abolishes the ethanol-induced activation of the TLR4/IL-1RI signaling pathway.
In summary, the present results demonstrate that low to moderate concentrations of ethanol are capable of stimulating TLR4/IL-1RI response,
and provide evidence of a novel mechanism by which ethanol, through its interaction with membrane rafts, can promote TLR4/IL-1RI recruitment and signaling."
a("anti-TLR4 Abs")  -| a(CHEBI:ethanol)
a("anti-TLR4 Abs") -| bp(GOBP:"cytokine production involved in inflammatory response")
a(CHEBI:saponin) -> tloc(complex(p(HGNC:TLR4),p(HGNC:IRAK1)),GOCC:cytoplasm,GOCC:"plasma membrane")
a("streptolysin-O") -> tloc(complex(p(HGNC:TLR4),p(HGNC:IRAK1)),GOCC:cytoplasm,GOCC:"plasma membrane")
a(CHEBI:saponin) -|  complex(p(HGNC:TLR4), bp(GOBP:"Toll signaling pathway"))
a("streptolysin-O") -| complex(p(HGNC:TLR4), bp(GOBP:"Toll signaling pathway"))
a(CHEBI:ethanol) -> p(HGNC:TLR4)
a(CHEBI:ethanol) -> bp(GOBP:"Toll signaling pathway")
UNSET Species
#############################################################3
SET Citation={"PubMed","J Neuroimmune Pharmacol. 2008 Mar;3(1):5-11. Epub 2007 Dec 5.","18066668"}
SET Evidence="Microglial cells respond to the herpes simplex virus (HSV)-1 by producing proinflammatory cytokines and chemokines. 
After this inflammatory burst, these cells undergo apoptotic cell death. 
We have recently demonstrated that both virus-induced immune mediator production and apoptosis were induced through Toll-like receptor 2 (TLR2) signaling."
SET Cell="microglial cell"
bp(GOBP:"response to virus") -> bp(GOBP:"cytokine production involved in inflammatory response")
bp(GOBP:"response to virus") -> bp(GOBP:"chemokinesis") 
bp(GOBP:"inflammatory cell apoptotic process") -> bp(GOBP:"programmed cell death")
bp(GOBP:"response to virus") -> bp(GOBP:"programmed cell death")
UNSET Cell

SET Evidence="Based upon these findings, we hypothesized that the inhibition of TLR2 signaling may serve as a means to alleviate excessive neuroinflammation.
In the present study, we cloned four vaccinia virus (VV) proteins, which have been reported to disrupt either TLR signaling or NF-kappaB activation,
and overexpressed them in HEK293T cells stably expressing murine TLR2 and in primary murine microglia. "
bp(GOBP:"toll-like receptor signaling pathway") negativeCorrelation path(ADO:neuroinflammation)
SET CellLine="HEK293T"
bp(GOBP:"response to virus") -| bp(GOBP:"toll-like receptor signaling pathway")
bp(GOBP:"response to virus") -| bp(GOBP:"positive regulation of NF-kappaB transcription factor activity ")                                  
UNSET CellLine

SET Evidence="Using an NF-kappaB-driven luciferase reporter gene assay, we show that upon stimulation with HSV and Listeria monocytogenes, 
all four vaccinia proteins inhibited TLR2 signaling with different levels of inhibition in the TLR2-expressing cell line and primary microglia.
We found similar results when microglial cells were stimulated with the TLR4 ligand LPS and the TLR9 ligand CpG ODN. Taken together, these data provide evidence that these VV proteins can function as inhibitors of TLR signaling in primary microglial cells"
bp(GOBP:"induction of host immune response by virus") -| p(HGNC:TLR2)
SET MeSHDisease="Bacterial Infections" 
bp(GOBP:" immune response ") -| p(HGNC:TLR2)
UNSET MeSHDisease
SET Cell="microglial cell"
complex(p(HGNC:TLR4),a(CHEBI:lipopolysaccharide)) -- bp(GOBP:"response to virus") 
complex(p(HGNC:TLR9),a("CpG oligodeoxynucleotides")) -- bp(GOBP:"response to virus") 
bp(GOBP:"response to virus")  -| bp(GOBP:"toll-like receptor signaling pathway")
UNSET Cell
###############################################3
SET Citation={"PubMed","Mult Scler. 2008 May;14(4):446-54. doi: 10.1177/1352458507085137. Epub 2008 Jan 21.","18208868"}
SET Evidence="Cerebrospinal fluid (CSF) concentrations of soluble human leukocyte antigen class I (HLA-I) (sHLA-I), HLA-G (sHLA-G)
and anti-apoptotic Fas (sFas) molecules were measured by enzyme linked immunosorbent assay technique in 65 relapsing-remitting (RR) MS patients classified according to clinical and magnetic resonance imaging (MRI) evidence of disease activity.
Sixty-four patients with other inflammatory neurological disorders (OIND) and 64 subjects with noninflammatory neurological disorders (NIND) served as controls.
CSF concentrations were higher in RRMS and in OIND than in NIND patients for sHLA-I (P < 0.02), greater in RRMS than in OIND and in NIND for sHLA-G (P < 0.001 and P < 0.01, respectively)
 and lower in RRMS than in OIND and in NIND for sFas (P < 0.001 and P < 0.02, respectively). "
SET Species ="9606"
SET Cell="leukocyte"
SET MeSHAnatomy="Cerebrospinal Fluid"
p(HGNC:"HLA-A") -- path(MESHD:"Acute Disease")
p(HGNC:FAS) -- path(MESHD:"Acute Disease")
UNSET Species
UNSET Cell
UNSET MeSHAnatomy
##################################################

SET Citation={"PubMed","J Immunol. 2008 Feb 15;180(4):2204-13.","18250427"}
SET Evidence="The neurotrophic cytokines ciliary neurotrophic factor and leukemia inhibitory factor (LIF) play a key role in neuronal and oligodendrocyte survival 
and as protective factors in neuroinflammation. To further elucidate the potential of endogenous LIF in modulating neuroinflammation,
 we studied myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in LIF knockout mice (LIF(-/-) mice). "
SET Cell="oligodendrocyte"
SET Cell="neuron"
bp(GOBP:"response to ciliary neurotrophic factor") -| path(ADO:neuroinflammation)
p(HGNC:LIF) -| path(ADO:neuroinflammation)
UNSET Cell
UNSET Cell

SET Evidence="In the late phase of active myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis,
 LIF(-/-) mice exhibited a markedly milder disease course. The inflammatory infiltrate in LIF(-/-) mice was characterized by an increase in neutrophilic granulocytes early 
and fewer infiltrating macrophages associated with less demyelination later in the disease."
SET Species="10090"
g(HGNC:MOG) -| p(HGNC:LIF) 
bp(GOBP:"inflammatory response") ->  bp(GOBP:"neutrophil activation")
bp(GOBP:"inflammatory response") -| bp(GOBP:"macrophage activation")

SET Evidence=" In good correlation with an effect of endogenous LIF on the immune response, we found an Ag-specific T cell-priming defect with impaired IFN-gamma production in LIF(-/-) mice. On the molecular level, 
the altered recruitment of inflammatory cells is associated with distinct patterns of chemokine production in LIF(-/-) mice with an increase of CXCL1 early and a decrease of CCL2, CCL3, and CXCL10 later in the disease."
p(HGNC:LIF) -> p(HGNC:CXCL1)
p(HGNC:LIF) -> p(HGNC:CCL2)
p(HGNC:LIF) -> p(HGNC:CCL3)
p(HGNC:LIF) -> p(MGI:Cxcl10)

SET Evidence="These data reveal that endogenous LIF is an immunologically active molecule in neuroinflammation.
This establishes a link between LIF and the immune system which was not observed in the ciliary neurotrophic factor knockout mouse."
p(HGNC:LIF) -> bp(GOBP:"activation of immune response")
bp(GOBP:"activation of immune response") -> path(ADO:neuroinflammation)
UNSET Species

##################################################################3
SET Citation={"PubMed","Eur J Nucl Med Mol Imaging. 2008 Mar;35 Suppl 1:S70-4. doi: 10.1007/s00259-007-0704-y.","18270700"}
SET Evidence="To study Alzheimer's disease (AD), a variety of mouse models has been generated through the overexpression of the amyloid precursor protein 
and/or the presenilins harboring one or several mutations found in familial AD. With aging, these mice develop several lesions similar to those of AD,
 including diffuse and neuritic amyloid deposits, cerebral amyloid angiopathy, dystrophic neurites and synapses, and amyloid-associated neuroinflammation. "
SET Species="10090"
p(HGNC:APP) -- path(DO:"Alzheimer's disease") 
path(DO:"Alzheimer's disease")  -- path(DO:"cerebral amyloid angiopathy")   
path(DO:"Alzheimer's disease") -- path(ADO:neuroinflammation)

SET Evidence="Other characteristics of AD, such as neurofibrillary tangles and nerve cell loss, are not satisfactorily reproduced in these models.
Mouse models that recapitulate only specific aspects of AD pathogenesis are of great advantage when deciphering the complexity of the disease and can contribute substantially to diagnostic and therapeutic innovations."
path(DO:"Alzheimer's disease")  -- path(ADO:"Neurofibrillary_tangle")

SET Evidence=" Incomplete mouse models have been key to the development of Abeta42-targeted therapies, as well as to the current understanding of the interrelationship 
between cerebral beta-amyloidosis and tau neurofibrillary lesions, and are currently being used to develop novel diagnostic agents for in vivo imaging."
SET Species="10090"
path(DO:"amyloidosis") -- bp(GOBP:"negative regulation of neurofibrillary tangle assembly")
UNSET Species
###################################################################
SET Citation={"PubMed","Curr Mol Med. 2007 Dec;7(8):735-42.","18331231"}
SET Evidence="This review focuses on the current findings regarding interaction between amyloid beta peptide (Abeta) and 
receptor for advanced glycation endproducts (RAGE) and its roles in the pathogenesis of Alzheimer's disease (AD).
As a ubiquitously expressed cell surface receptor, RAGE mediates the effects of Abeta on microglia, blood-brain barrier (BBB)
 and neurons through activating different signaling pathways."
SET Cell="microglial cell"
SET MeSHAnatomy="Blood-Brain Barrier"
p(HGNC:AGER) -> act(a(ADO:"Abeta_42"))
UNSET Cell
UNSET MeSHAnatomy

SET Evidence="Data from autopsy brain tissues, in vitro cell cultures and transgenic mouse models suggest that Abeta-RAGE interaction 
exaggerates neuronal stress, accumulation of Abeta, impaired learning memory, and neuroinflammation.
 Blockade of RAGE protects against Abeta-mediated cellular perturbation. These findings may have an important therapeutic implication for neurodegenerative disorders relevant to AD."
SET Species="10090"
a(ADO:"Abeta_42") -> bp(MESHPP:"Oxidative Stress")
p(HGNC:AGER)-> bp(MESHPP:"Oxidative Stress")
a(ADO:"Abeta_42") positiveCorrelation bp(GOBP:" learning or memory")
a(ADO:"Abeta_42") positiveCorrelation path(ADO:neuroinflammation)
SET Disease="neurodegenerative disease"
a(ADO:"Abeta_42") ->  path(MESHD:"Neurodegenerative Diseases")
p(HGNC:AGER) -> path(MESHD:"Neurodegenerative Diseases")
UNSET Species
############################################################################3
SET Citation={"PubMed","J Biol Chem. 2008 Jun 13;283(24):16752-61. doi: 10.1074/jbc.M710530200. Epub 2008 Apr 16.","18417477"}
SET Evidence="Inflammatory bowel disease arises from the interplay between luminal bacteria and the colonic mucosa. 
Targeted inhibition of pro-inflammatory pathways without global immunosuppression is highly desirable.
 Apolipoprotein (apo) E has immunomodulatory effects and synthetically derived apoE-mimetic peptides are 
beneficial in models of sepsis and neuroinflammation. 
Citrobacter rodentium is the rodent equivalent of enteropathogenic Escherichia coli, and it causes colitis in mice by colonizing the surface of colonic epithelial cells and inducing signaling events."
SET Species="10090"
SET MeSHDisease="Bacterial Infections" 
SET Anatomy="colonic mucosa"
p(HGNC:APOE) -- path(ADO:neuroinflammation)
p(HGNC:APOE) -- path(MESHD:Sepsis)
UNSET MeSHDisease
UNSET Anatomy
path(MESHD:"Escherichia coli Infections") -> path(MESHD:Colitis)

SET Evidence="We have reported that mice deficient in inducible nitric-oxide (NO) synthase (iNOS) have attenuated C. rodentium-induced colitis. We used young adult mouse colon (YAMC) cells 
that mimic primary colonic epithelial cells to study effects of an antennapedia-linked apoE-mimetic peptide, COG112, on C. rodentium-activated cells. COG112 significantly attenuated induction of NO production, and iNOS mRNA and protein expression, in a concentration-dependent manner."
SET MeSHDisease="Bacterial Infections" 
a(CHEBI:"nitric oxide") -| path(MESHD:Colitis)
UNSET MeSHDisease
SET Cell="colon epithelial cell"
complex(a("HOM-C"),p(HGNC:APOE), a("COG112-peptide")) -| a(CHEBI:"nitric oxide")
UNSET Species
UNSET Cell

SET Evidence="COG112 inhibited the C. rodentium-stimulated induction of 
iNOS and the CXC chemokines KC and MIP-2 to the same degree as the NF-kappaB inhibitors MG132 or BAY 11-7082, and there was no additive effect when COG112 and these inhibitors were combined. COG112 significantly reduced nuclear translocation of NF-kappaB, when assessed by electromobility shift assay, immunoblotting, and immunofluorescence for p65. This correlated with inhibition of both C. rodentium-stimulated IkappaB-alpha phosphorylation and degradation, and IkappaB kinase activity, which occurred by inhibition of IkappaB kinase complex formation rather than by a direct effect on the enzyme itself. These studies indicate that apoE-mimetic peptides may have novel therapeutic potential by inhibiting NF-kappaB-driven proinflammatory epithelial responses to pathogenic colonic bacteria."
SET MeSHDisease="Bacterial Infections" 
a("COG112-peptide") -| p(HGNC:NOS2) 
a("COG112-peptide") -| bp(HGNC:CXCL2)
a("COG112-peptide") -- bp(GOBP:"negative regulation of neutrophil chemotaxis")
UNSET MeSHDisease

#######################################################
SET Citation={"PubMed","Proc Natl Acad Sci U S A. 2008 May 27;105(21):7534-9. doi: 10.1073/pnas.0802865105. Epub 2008 May 19.","18490655"}
SET Evidence="nducible nitric oxide synthase (iNOS) is one of three key enzymes generating nitric oxide (NO) from the amino acid l-arginine. 
iNOS-derived NO plays an important role in numerous physiological (e.g. blood pressure regulation, wound repair and host defence mechanisms)
and pathophysiological (inflammation, infection, neoplastic diseases, liver cirrhosis, diabetes) conditions."
p(HGNC:NOS2)  -> a(CHEBI:"nitric oxide")
a(CHEBI:"nitric oxide") -- bp(GOBP:"regulation of blood pressure")
a(CHEBI:"nitric oxide") -- bp(GOBP:"wound healing ")
a(CHEBI:"nitric oxide") -- path(MESHD:Inflammation)
a(CHEBI:"nitric oxide") -- path(MESHD:"Liver Cirrhosis")
a(CHEBI:"nitric oxide") -- path(ADO:diabetes)

SET Evidence=" In particular, pivotal effects such as malingnant transformation, angiogenesis, and metastasis are modulated by iNOS.
 On the other hand, NO derived from macrophages has a potentially cytotoxic/cytostatic effect upon tumor cells. Hence, therapeutical interference with iNOS activity is of considerable interest, especially in tumors where metastatic activity, host defence mechanisms and the level of differentiation seem to be correlated to iNOS expression. This review will aim to summarize the dual actions of iNOS as simultaneous tumor promoter and suppressor."
SET Cell="macrophage"
a(CHEBI:"nitric oxide") -- bp(MESHPP:"Cytotoxicity, Immunologic")
UNSET Cell

#######################################################

SET Citation={"PubMed","J Immunol. 2008 Jul 1;181(1):680-9.","18566435"}
SET Evidence="Because chronic neuroinflammation is a hallmark of neurodegenerative diseases and compromises neuron viability,
 it is imperative to discover pharmacologic targets to modulate the activation of immune brain cells, the microglia. 
In this study, we identify the transcription factor Nrf2, guardian of redox homeostasis, as such target in a model of LPS-induced inflammation in mouse hippocampus. Nrf2 knockout mice were hypersensitive to the neuroinflammation induced by LPS, as determined by an increase in F4/80 mRNA and protein, indicative of an increase in microglial cells, and in the inflammation markers inducible NO synthase, IL-6, and TNF-alpha, compared with the hippocampi of wild-type littermates."
SET Species="10090"
path(ADO:neuroinflammation) biomarkerFor path(MESHD:"Neurodegenerative Diseases")
p(HGNC:NFE2L2 ) isA a(CHEBI:lipopolysaccharide)
p(HGNC:NFE2L2 ) -- bp(MESHPP:Homeostasis)
p(HGNC:NFE2L2 ) -- path(MESHD:Inflammation)
UNSET Species

SET Evidence="The aliphatic isothiocyanate sulforaphane elicited an Nrf2-mediated antioxidant response in the BV2 microglial cell line,
 determined by flow cytometry of cells incubated with the redox sensitive probe dihydrodichlorofluorescein diacetate, and by the Nrf2-dependent induction of the phase II antioxidant enzyme heme oxygenase-1. Animals treated with sulforaphane displayed a 2-3-fold increase in heme oxygenase-1, a reduced abundance of microglial cells in the hippocampus and an attenuated production of inflammation markers (inducible NO synthase, IL-6, and TNF-alpha) in response to LPS."
SET Cell="microglial cell"
SET CellLine="MEF (C57BL/6) cell"
complex(a(CHEBI:sulforaphane),p(HGNC:NFE2L2 )) -- bp(MESHPP:"Antioxidant Response Elements")
UNSET Species
UNSET Cell
UNSET CellLine

SET Evidence="Considering that release of reactive oxygen species is a property of activated microglia,
 we propose a model in which late induction of Nrf2 intervenes in the down-regulation of microglia. 
This study opens the possibility of targeting Nrf2 in brain as a means to modulate neuroinflammation."
p(HGNC:NFE2L2)-- path(ADO:neuroinflammation) 
#################################################3
SET Citation={"PubMed","J Neurosci. 2008 Jul 23;28(30):7687-98. doi: 10.1523/JNEUROSCI.0143-07.2008.","18650345"}
SET Evidence="alpha-Synuclein (SYN) is the major component of Lewy bodies, the neuropathological hallmarks of Parkinson's disease (PD). 
Missense mutations and multiplications of the SYN gene cause autosomal dominant inherited PD. Thus, SYN is implicated in the pathogenesis of PD.
 However, the mechanism whereby SYN promotes neurodegeneration remains unclear."
SET NervousSystem="Lewy Bodies"
p(HGNC:SNCA) biomarkerFor path(DO:"Parkinson's disease")
UNSET NervousSystem

SET Evidence="Familial PD with SYN gene mutations are rare because the majority of PD is sporadic and emerging evidence indicates that sporadic PD may result from genetic and environmental risk factors including neuroinflammation. 
Hence, we examined the relationship between SYN dysfunction and neuroinflammation in mediating dopaminergic neurodegeneration in mice and dopaminergic neuronal cultures derived from wild-type SYN and mutant A53T SYN transgenic mice in a murine SYN-null (SYNKO) background (M7KO and M83KO, respectively)."
SET Species="10090"
p(HGNC:SNCA)-- path(ADO:neuroinflammation)

SET Evidence=" Stereotaxic injection of an inflammagen, lipopolysaccharide, into substantia nigra of these SYN genetically engineered mice induced similar inflammatory reactions.
In M7KO and M83KO, but not in SYNKO mice, the neuroinflammation was associated with dopaminergic neuronal death and the accumulation of insoluble aggregated SYN as cytoplasmic inclusions in nigral neurons."
SET Cell={"neuron of the substantia nigra","dopaminergic neuron"}
a(CHEBI:lipopolysaccharide) -- bp(GOBP:"inflammatory response")
path(ADO:neuroinflammation) -- bp(GOBP:"neuron death")
UNSET Cell

SET Evidence=" Nitrated/oxidized SYN was detected in these inclusions and abatement of microglia-derived nitric oxide and superoxide provided significant neuroprotection in neuron-glia cultures from M7KO mice.
 These data suggest that nitric oxide and superoxide released by activated microglia may be mediators that link inflammation and abnormal SYN in mechanisms of PD neurodegeneration.
 This study advances understanding of the role of neuroinflammation and abnormal SYN in the pathogenesis of PD and opens new avenues for the discovery of more effective therapies for PD."
SET Cell="microglial cell"
a(CHEBI:"nitric oxide") positiveCorrelation bp(GOBP:"inflammatory response")
a(CHEBI:superoxide) positiveCorrelation bp(GOBP:"inflammatory response")
UNSET Species
UNSET Cell

#################################################3

UNSET STATEMENT_GROUP

